DCVAC/OvCa

Drug Profile

DCVAC/OvCa

Alternative Names: Dendritic cell vaccine/Ovarian cancer - Sotio

Latest Information Update: 02 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SOTIO
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer

Most Recent Events

  • 02 Jul 2018 Safety and efficacy data from phase II trial in Ovarian carcinoma presented at 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 03 Jun 2018 Positive efficacy and safety data from the phase II SOV01 trial in Ovarian cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology
  • 28 Mar 2018 EMA's Committee for Orphan Medicinal Products (COMP) issues a positive opinion to recommend orphan drug designation for DCVAC/OvCa for Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top